PCN140 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SWITZERLAND
Abstract
Authors
C. Oniangue-Ndza R. Schneider B. Malcolm J. May K.M. Gooden S. Klijn E. Cakar